Biocompatibility and safety of a hybrid core-shell nanoparticulate OP-1 delivery system intramuscularly administered in rats

Biomaterials

Volumn 31, Issue 10, 2010, Pages 2746-2754

  Haidar, Ziyad S ^a,b,c   Hamdy, Reggie C ^a,c   Tabrizian, Maryam ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Biocompatibility; BMP; Drug delivery; Foreign body response; Haemocompatibility; Nanoparticle

Indexed keywords

ADVERSE EFFECT; ALTERNATING LAYERS; BIOCHEMICAL ANALYSIS; BLOOD SAMPLES; BODY WEIGHT; BONE GROWTH; CATIONIC NANOPARTICLES; CELL VIABILITY; CONTROLLED DELIVERY; CYTOCOMPATIBILITY; DELIVERY SYSTEMS; FOREIGN BODY RESPONSE; GROWTH FACTOR; HAEMOCOMPATIBILITY; HEALTH EFFECTS; HYBRID CORE-SHELL; IMMUNE RESPONSE; IN-VIVO; MC3T3-E1; MONODISPERSE; NANO PARTICULATES; ORGAN FUNCTIONS; OSTEOGENIC PROTEINS; PATHOLOGICAL CHANGES; PREOSTEOBLASTS; SELF-ASSEMBLED; SHELF LIFE; WISTAR RAT;

ANIMALS; BIOACTIVITY; BIOCOMPATIBILITY; DRUG DELIVERY; PEPTIDES; RATS;

NANOPARTICLES;

NANOPARTICLE; NANOSHELL; OSTEOGENIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY TESTING; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; BONE MORPHOGENETIC PROTEIN 7; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; MALE; MATERIALS TESTING; MUSCLES; NANOPARTICLES; ORGAN SIZE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 75149154315     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.12.034     Document Type: Article

References (50)

1. Bessa P.C., Casal M., and Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2 (2008) 1-13
2. Mont M.A., Ragland P.S., Biggins B., Friedlaender G., Patel T., Cook S., et al. Use of bone morphogenetic proteins for musculoskeletal applications: an overview. J Bone Joint Surg 86 (2004) 41-55
3. Termaat M.F., Den Boer F.C., Bakker F.C., Patka P., and Haarman H.J. Bone morphogenetic proteins: development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 87 (2005) 1367-1378
4. Bessa P.C., Casal M., and Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2 (2008) 81-96
5. Luginbuehl V., Meinel L., Merkle H.P., and Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 58 (2004) 197-208
6. Illum L., and Davis S.S. Drug delivery. Curr Opin Biotechnol 2 (1991) 254-259
7. Chaize B., Colletier J.P., Winterhalter M., and Fournier D. Encapsulation of enzymes in liposomes: high encapsulation efficiency and control of substrate permeability. Artif Cells Blood Substit Immobil Biotechnol 32 (2004) 67-75
8. Takeuchi H., Kojima H., Yamamoto H., and Kawashima Y. Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats. J Control Release 68 (2000) 195-205
9. ® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609 (2003) 102-108
10. Haidar Z.S., Hamdy R.C., and Tabrizian M. Protein release kinetics for core-shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomes. Biomaterials 29 (2008) 1207-1215
11. Haidar Z.S., Azari F., Hamdy R.C., and Tabrizian M. Modulated release of OP-1 and enhanced preosteoblast differentiation using a core-shell nanoparticulate system. J Biomed Mater Res A 31 (2009) 1817-1824
12. Kim J.S., Yoon T.J., Yu K.N., Kim B.G., Park S.J., Kim H.W., et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 89 (2006) 338-347
13. Haidar ZS, Tabrizian M, Hamdy RC. A hybrid OP-1 delivery system enhances new bone regeneration and consolidation in a rabbit model of distraction osteogenesis. Growth Factors, in press [Epub ahead of print].
14. Gref R., Minamitake Y., Perracchia M.T., Trubeskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
15. Desai M.P., Labhasetwar V., Amidon G.L., and Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13 (1996) 1838-1845
16. Fabian E., Landsiedel R., Ma-Hock L., Wiench K., Wohlleben W., and van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 82 (2008) 151-157
17. De Souza R., Zahedi P., Allen C.J., and Piquette-Miller M. Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials 30 (2009) 3818-3824
18. Hamdy R.C., Amako M., Beckman L., Kawaguchi M., Rauch F., Lauzier D., et al. Effects of osteogenic protein-1 on distraction osteogenesis in rabbits. Bone 33 (2003) 248-255
19. Haque T., Mandu-Hrit M., Rauch F., Lauzier D., Tabrizian M., and Hamdy R. Immunohistochemical localization of BMP signaling Smads during long-bone distraction osteogenesis. J Histochem Cytochem 54 (2005) 407-415
20. Mandu-Hrit M., Haque T., Lauzier D., Kotsiopriftis M., Rauch F., Tabrizian M., et al. Early injection of OP-1 during distraction osteogenesis accelerates new bone formation in rabbits. Growth Factors 24 (2006) 172-183
21. Stokes W.S. Humane endpoints for laboratory animals used in toxicity testing. ILAR J 43 (2002) 31-38
22. Aubert A.E., Vandeput S., Beckers F., Liu J., Verheyden B., and Van Huffel S. Complexity of cardiovascular regulation in small animals. Philos Transact A Math Phys Eng Sci 367 (2009) 1239-1250
23. Wang H.P., Liang Y.J., Long D.X., Chen J.X., Hou W.Y., and Wu Y.J. Metabolic profiles of serum from rats after subchronic exposure to chlorpyrifos and carbaryl. Chem Res Toxicol 22 (2009) 1026-1033
24. Wildemann B., Kandziora F., Krummrey G., Palasdies N., Haas N.P., Raschke M., et al. Local and controlled release of growth factors (combination of IGF-I and TGF-beta I, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle. J Control Release 5 (2004) 249-256
25. Oda S., Kinoshita A., Higuchi T., Shizuya T., and Ishikawa I. Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2). J Med Dent Sci 44 (1997) 53-62
26. Takeuchi H., Kojima H., Yamamoto H., and Kawashima Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75 (2001) 83-91
27. Yang K.C., Wu C.C., Lin F.H., Qi Z., Kuo T.F., Cheng Y.H., et al. Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. Xenotransplantation 15 (2008) 407-416
28. Sells D.M., Brix A.E., Nyska A., Jokinen M.P., Orzech D.P., and Walker N.J. Respiratory tract lesions in noninhalation studies. Toxicol Pathol 35 (2007) 170-177
29. Mohr U., Dungworth D.L., and Capen C.C. In: Mohr U., and Dungworth D.L. (Eds). Pathobiology of the aging rat (1992), Intl Life Sciences Inst (ILSI) Press, Washington, DC 485-488
30. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 31 (2001) 81-110. http://arjournals.annualreviews.org
31. Urist M.R. Bone: formation by autoinduction. Science 150 (1965) 893-899
32. Yamamoto M., Tabata Y., and Ikada Y. Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed 9 (1998) 439-458
33. Nakagawa T., and Tagawa T. Ultrastructural study of direct bone formation induced by BMPs-collagen complex implanted into an ectopic site. Oral Dis 6 (2000) 172-179
34. Okubo Y., Bessho K., Fujimura K., Konishi Y., Kusumoto K., Ogawa Y., et al. Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int J Oral Maxillofac Surg 29 (2000) 62-66
35. Kurokawa I., Kusumoto K., Bessho K., Okubo Y., Senzaki H., and Tsubura A. Immunohistochemical expression of bone morphogenetic protein-2 in pilomatricoma. Br J Dermatol 143 (2000) 754-758
36. Nakagawa T., Sugiyama T., Kamei T., Murata T., and Tagawa T. An immuno-light- and electron-microscopic study of the expression of bone morphogenetic protein-2 during the process of ectopic bone formation in the rat. Arch Oral Biol 46 (2001) 403-411
37. Kusumoto K., Bessho K., Fujimura K., Akioka J., Okubo Y., Wang Y., et al. Osteoinduction by recombinant human bone morphogenetic protein-2 in muscles of non-human primates. J Int Med Res 30 (2002) 251-259
38. Wysocki R.W., and Cohen M.S. Ectopic ossification of the triceps muscle after application of bone morphogenetic protein-7 to the distal humerus for recalcitrant nonunion: a case report. J Hand Surg Am 32 (2007) 647-650
39. Nanno K., Sugiyasu K., Daimon T., Yoshikawa H., and Myoui A. Synthetic alginate is a carrier of OP-1 for bone induction. Clin Orthop Relat Res 467 (2009) 3149-3155
40. Stoeger T., Proetzel G.E., Welzel H., Papadimitriou A., Dony C., Balling R., et al. In situ gene expression analysis during BMP2-induced ectopic bone formation in mice shows simultaneous endochondral and intramembranous ossification. Growth Factors 20 (2002) 197-210
41. Yoshida K., Bessho K., Fujimura K., Kusumoto K., Ogawa Y., Tani Y., et al. Osteoinduction capability of recombinant human bone morphogenetic protein-2 in intramuscular and subcutaneous sites: an experimental study. J Craniomaxillofac Surg 26 (1998) 112-115
42. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., et al. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res 50 (2000) 227-238
43. Bessho K., Carnes D.L., Cavin R., and Ong J.L. Experimental studies on bone induction using low-molecular-weight poly(dl-lactide-co-glycolide) as a carrier for recombinant human bone morphogenetic protein-2. J Biomed Mater Res 61 (2002) 62-65
44. Yamamoto M., Takahashi Y., and Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24 (2003) 4375-4388
45. Carano R.A.D., and Filvaroff E.H. Angiogenesis and bone repair. Drug Discov Today 8 (2003) 980-989
46. David L., Feige J.J., and Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20 (2009) 203-212
47. Deckers M.M.L., van Bezooijen R.L., van der Horst G., Hoogendam J., van der Bent C., Papapoulos S.E., et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143 (2002) 1545-1553
48. Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068 (2006) 19-25
49. Tsialogiannis E., Polyzois I., Oak Tang Q., Pavlou G., Tsiridis E., Heliotis M., et al. Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 13 (2009) 123-137
50. Aspenberg P., and Turek T. BMP-2 for intramuscular bone induction: effect in squirrel monkeys is dependent on implantation site. Acta Orthop Scand 67 (1996) 3-6